# DermTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dermtech

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.dermtech.com
- Total disclosed funding: $16M
- Latest round: Series C (Nov 1, 2017)
- Investors on record: 2

## About

DermTech, Inc. specializes in genomic testing services, focusing on melanoma detection through non-invasive methods. Their innovative solutions aim to enhance dermatological assessments and patient care. DermTech, Inc. was founded in 1996 in the US, focusing on genomic testing services. The company has evolved its business strategy over the years but does not have known significant pivots. The latest funding round was a Private Placement in January 2021, where the company raised USD 143.70 mn by selling 29.50 million shares at USD 4.87 per share. DermTech, Inc. offers genomic testing services, prominently featuring the DermTech Melanoma Test, which uses DermTech Smart Stickers for non-invasive sample collection from skin lesions. This test provides dermatologists with objective genomic data essential for assessing melanoma risk. The product is available without out-of-pocket costs for Medicare beneficiaries, with a customer base that includes dermatologists, primary care physicians, and medical institutions. The company generates revenue primarily through its genomic testing services, particularly the DermTech Melanoma Test, utilizing a transaction structure that engages healthcare providers, primarily through reimbursements from insurance providers like Medicare.

## Funding rounds

- Series C, Nov 1, 2017, $10M — RTW Investments
- Series B, Aug 8, 2013, $5.8M — Jacobs Investments

## Investors

- Jacobs Investments (https://capitalatlas.ai/funds/jacobs-investments) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C